[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.161.216.242. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Contempo 1999
December 8, 1999

Anthrax VaccineEvidence for Safety and Efficacy Against Inhalational Anthrax

Author Affiliations

Author Affiliations: US Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, Md.

 

Edited by Thomas C. Jefferson, MD, Contributing Editor, JAMA.

JAMA. 1999;282(22):2104-2106. doi:10.1001/jama.282.22.2104

Several countries are believed to have biological weapons programs capable of causing widespread devastating illness among unprotected individuals. Bacillus anthracis, the causative agent of anthrax, is one of the most likely pathogens to be used.1 The decision by Secretary of Defense William S. Cohen to vaccinate the US Armed Forces against anthrax, using a licensed vaccine with which most civilian and military medical personnel were unfamiliar, prompts this review of the evidence of the safety and efficacy of the vaccine (anthrax vaccine adsorbed [AVA]).

First Page Preview View Large
First page PDF preview
First page PDF preview
×